

For patients, with patients

- PMDA is further endeavoring “Patients First” in 2022 -

4th January, 2022

I wish all of you have a Happy New Year in 2022!

Back to last year, it was much turbulent year in 2021, following 2020, which were affected from the COVID-19 pandemic. While Japanese people and society were forced to change by the pandemic, the PMDA has continuously been working to guide regulatory directions as a Japanese regulatory authority in a prompt and agile manner.

Through the numerous Statements by the Chief Executive of PMDA, I have delivered you PMDA’s efforts how we have been combatting SARS-CoV-2 infection. And, PMDA has been taking actions to respond quickly to Japanese society’s needs, such as offering of free scientific advice for the development of COVID-19 vaccines, introduction of remote inspections, and promotion of digitalization which is just changing worldwide. Besides COVID-19 related efforts, I emphasize PMDA has also been proceeding various significant activities continuously such as to promote patient involvement, early deployment of software as a medical device.

In order to ensure transparency, I disclosed these activities information in-writing to the public. PMDA is continuing to make every effort to translate these information into English and to distribute in timely manner for not only Japanese people but also global stakeholders. Evaluation tools for COVID-19 is critical to be considered of course,

further, I stress that working together with our stakeholders, including public and patients, will also make us enhance more and better.

My philosophy as Chief Executive of PMDA is to proceed “4 Firsts” and the first concept of them is “Patient first”. This is based on the concept of performing our tasks through establishing good and open communication in clinical settings to prioritize patient satisfaction. I have confidence that PMDA is able to fulfill its responsibilities as a regulatory authority by quickly responding to the changes in society through close collaboration with, especially, public and patients this year.

Once again, I wish all of you have a happy, healthy, and prosperous new year.

FUJIWARA Yasuhiro, MD, PhD

Chief Executive

Pharmaceuticals and Medical Devices Agency